Merck to seek authorisation for oral Covid-19 drug
Pharmaceutical company Merck said Friday it will seek authorisation in the US for an oral drug for Covid-19, after the pill showed “compelling results” in a clinical trial.
The experimental drug, molnupiravir, significantly reduced the risk of hospitalisation or death when administered to high-risk patients early in the disease, Merck and its partner Ridgeback Biotherapeutics said in a statement.
“At the interim analysis, 7.3 percent of patients who received molnupiravir were hospitalised through Day 29, compared with 14.1 percent of placebo-treated patients who were hospitalised or died.”
The phase three clinical trial evaluated data from 775 patients with laboratory-confirmed mild to moderate Covid.
“Merck plans to seek emergency use authorisation in the US as soon as possible and to submit applications to regulatory agencies worldwide,” the companies said.
Molnupiravir, one of the several oral pills for Covid-19 being developed, is meant to stop the virus from replicating.
Facebook "unquestionably making hate worse": whistleblower Haugen
Facebook’s data scientist turned whistleblower, Frances Haugen testifying before the online safety...
Researchers propose 3D printing approach to develop high-strength titanium alloy
BEIJING: Researchers have proposed a 3D printing strategy to develop titanium alloy...
She Loves Tech 2021: Empowering the women of Pakistan through technology
Groundbreaking start-up 'CIRCLE', brought She Loves Tech 2021, a women-centric global technology start-up...
Russian agency targeting numerous US networks, Microsoft
Microsoft, in a recent blog post claims, Russia-owned agency is targeting hundreds...
Facebook whistleblower Haugen summoned to testify
In the wake of current Facebook-Haugen controversy, the employee turned whistleblower, Frances...